argenex (NASDAQ:ARGX) Receives Neutral Rating from Robert W. Baird

argenex (NASDAQ:ARGX)‘s stock had its “neutral” rating reiterated by research analysts at Robert W. Baird in a note issued to investors on Thursday,Benzinga reports. They currently have a $858.00 price objective on the stock, down from their previous price objective of $924.00. Robert W. Baird’s target price points to a potential downside of 0.47% from the stock’s previous close.

ARGX has been the topic of several other research reports. Citigroup upped their target price on shares of argenex from $1,041.00 to $1,124.00 and gave the company a “buy” rating in a research note on Monday, November 17th. HC Wainwright increased their price objective on shares of argenex from $774.00 to $915.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Wells Fargo & Company raised their target price on shares of argenex from $1,095.00 to $1,316.00 and gave the stock an “overweight” rating in a report on Thursday, December 11th. Royal Bank Of Canada boosted their target price on shares of argenex from $860.00 to $925.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Bank of America increased their price target on argenex from $880.00 to $887.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, argenex presently has a consensus rating of “Moderate Buy” and a consensus price target of $982.33.

argenex Trading Up 1.2%

argenex stock opened at $862.05 on Thursday. argenex has a 12 month low of $510.05 and a 12 month high of $934.62. The stock has a fifty day simple moving average of $866.88 and a two-hundred day simple moving average of $723.04. The firm has a market cap of $53.08 billion, a price-to-earnings ratio of 37.01, a PEG ratio of 0.86 and a beta of 0.37.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.37 by $0.03. argenex had a return on equity of 29.78% and a net margin of 41.58%.The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.07 billion. On average, equities research analysts forecast that argenex will post 3.13 EPS for the current fiscal year.

Institutional Investors Weigh In On argenex

A number of hedge funds have recently modified their holdings of the business. Ameriflex Group Inc. bought a new position in argenex in the 3rd quarter worth $32,000. Sunbelt Securities Inc. purchased a new stake in argenex in the third quarter worth about $36,000. WPG Advisers LLC bought a new position in shares of argenex in the first quarter worth about $37,000. Brooklyn Investment Group lifted its position in shares of argenex by 102.7% during the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock valued at $44,000 after buying an additional 38 shares in the last quarter. Finally, Bessemer Group Inc. lifted its position in shares of argenex by 276.5% during the 3rd quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock valued at $47,000 after buying an additional 47 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.